$0.01
(Market cap
$85 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
3.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-3.7
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.6
-
Face value
--
-
Shares outstanding
77,795,249
10 Years Aggregate
CFO
$-219.70 Mln
EBITDA
$-265.42 Mln
Net Profit
$-264.49 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cardiff Oncology (CRDF)
| -61.2 | 16.7 | -22.1 | -44.4 | -16.2 | -32.1 | -44.0 |
|
BSE Sensex*
| -10.6 | -3.6 | 1.9 | -6.2 | 4.5 | 5.4 | 10.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Cardiff Oncology (CRDF)
| -35.3 | 190.7 | 5.7 | -76.7 | -66.6 | 1,350.8 | -60.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cardiff Oncology (CRDF)
|
1.1 | 84.8 | 0.5 | -40.1 | -7,884.1 | -111.4 | -- | 3.1 |
| 86.3 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 270.6 | 17,746.8 | 1,054.4 | 755.9 | 5.7 | -- | 20.9 | 10.5 | |
| 72.7 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 59.0 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 110.2 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 358.2 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 117.4 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 541.1 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 591.3 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 |
Shareholding Pattern
View DetailsAbout Cardiff Oncology (CRDF)
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for... treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California. Read more
-
CEO & Director
Dr. Mark Erlander Ph.D.
-
CEO & Director
Dr. Mark Erlander Ph.D.
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Cardiff Oncology (CRDF)
What is the current share price of Cardiff Oncology Inc (CRDF) Today?
The share price of Cardiff Oncology Inc (CRDF) is $1.09 (NASDAQ) as of 04-Sep-2026 16:00 EDT. Cardiff Oncology Inc (CRDF) has given a return of -16.17% in the last 3 years.
What is the current PB & PE ratio of Cardiff Oncology Inc (CRDF)?
Since, TTM earnings of Cardiff Oncology Inc (CRDF) is negative, P/E ratio is not available.
The P/B ratio of Cardiff Oncology Inc (CRDF) is 3.11 times as on 04-Sep-2026, a 42 discount to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-4.10 |
4.14 |
2024 |
-4.55 |
2.49 |
2023 |
-1.60 |
0.95 |
2022 |
-1.62 |
0.59 |
2021 |
-8.63 |
1.74 |
What is the 52 Week High and Low of Cardiff Oncology Inc (CRDF)?
The 52-week high and low of Cardiff Oncology Inc (CRDF) are Rs 3.31 and Rs 0.76 as of 08-Sep-2026.
What is the market cap of Cardiff Oncology Inc (CRDF)?
Cardiff Oncology Inc (CRDF) has a market capitalisation of $ 85 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Cardiff Oncology Inc (CRDF)?
Before investing in Cardiff Oncology Inc (CRDF), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.